Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.28
Dollar change
-0.01
Percentage change
-0.78
%
IndexRUT P/E- EPS (ttm)-2.14 Insider Own18.20% Shs Outstand87.75M Perf Week-2.29%
Market Cap112.47M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float71.88M Perf Month-20.00%
Income-185.70M PEG- EPS next Q-0.46 Inst Own73.64% Short Float7.79% Perf Quarter-53.11%
Sales0.00M P/S- EPS this Y43.34% Inst Trans64.72% Short Ratio3.72 Perf Half Y-40.74%
Book/sh1.92 P/B0.67 EPS next Y41.07% ROA-58.95% Short Interest5.60M Perf Year-71.87%
Cash/sh1.94 P/C0.66 EPS next 5Y26.70% ROE-77.50% 52W Range1.00 - 5.64 Perf YTD-53.11%
Dividend Est.- P/FCF- EPS past 5Y0.51% ROI-89.70% 52W High-77.30% Beta0.80
Dividend TTM- Quick Ratio4.92 Sales past 5Y0.00% Gross Margin- 52W Low28.00% ATR (14)0.12
Dividend Ex-Date- Current Ratio4.92 EPS Y/Y TTM61.37% Oper. Margin0.00% RSI (14)44.34 Volatility7.21% 9.22%
Employees131 Debt/Eq0.25 Sales Y/Y TTM- Profit Margin- Recom2.56 Target Price2.90
Option/ShortYes / Yes LT Debt/Eq0.23 EPS Q/Q-41.67% Payout- Rel Volume0.22 Prev Close1.29
Sales Surprise- EPS Surprise-49.88% Sales Q/Q- EarningsMar 14 AMC Avg Volume1.51M Price1.28
SMA20-6.48% SMA50-2.72% SMA200-52.26% Trades Volume337,864 Change-0.78%
Date Action Analyst Rating Change Price Target Change
Jan-17-24Downgrade Jefferies Buy → Hold $6 → $1.50
Jan-16-24Downgrade Cantor Fitzgerald Overweight → Neutral
Dec-18-23Upgrade William Blair Mkt Perform → Outperform
Dec-08-23Resumed Jefferies Buy $9 → $6
Sep-27-23Initiated JMP Securities Mkt Outperform $11
May-12-23Upgrade Jefferies Hold → Buy $6 → $9
Mar-07-23Initiated Piper Sandler Overweight $22
Sep-12-22Downgrade SMBC Nikko Neutral → Underperform $2
Dec-22-21Downgrade William Blair Outperform → Mkt Perform
Dec-22-21Downgrade SVB Leerink Outperform → Mkt Perform $17
Mar-16-24 05:31AM
Mar-14-24 09:54PM
04:02PM
Feb-26-24 07:02AM
Feb-12-24 07:02AM
09:35AM Loading…
Jan-18-24 09:35AM
Jan-17-24 12:10PM
Jan-16-24 11:36AM
09:40AM
09:28AM
07:27AM
07:17AM
07:02AM
07:00AM
05:09AM
05:01PM Loading…
Nov-13-23 05:01PM
04:02PM
Sep-27-23 12:10PM
Aug-30-23 04:05PM
Aug-09-23 04:02PM
Aug-02-23 04:05PM
08:20AM
Jun-12-23 07:02AM
Jun-05-23 07:02AM
May-13-23 08:05AM
May-12-23 05:00PM
May-09-23 04:02PM
Mar-07-23 04:05PM
Mar-06-23 04:02PM
Jan-26-23 05:33AM
11:35AM Loading…
Dec-15-22 11:35AM
Dec-09-22 12:00PM
Nov-29-22 07:02AM
Nov-10-22 09:02AM
Nov-07-22 04:05PM
Oct-14-22 06:35PM
Sep-30-22 11:48AM
Sep-24-22 08:32AM
Sep-19-22 07:00AM
Sep-12-22 07:02AM
Sep-09-22 08:47AM
07:00AM
Aug-31-22 02:10PM
Aug-04-22 04:04PM
Jul-25-22 04:05PM
Jul-08-22 10:18AM
May-06-22 04:05PM
Apr-28-22 06:00PM
Apr-19-22 06:15PM
Apr-12-22 06:15PM
Apr-09-22 10:03AM
Mar-28-22 06:15PM
Mar-22-22 06:15PM
Mar-15-22 06:00PM
Mar-07-22 10:39AM
Mar-03-22 11:05AM
Mar-01-22 04:05PM
Feb-25-22 06:00PM
Feb-21-22 09:53AM
Feb-17-22 02:38AM
Feb-08-22 01:38PM
Feb-07-22 01:38PM
Feb-04-22 06:00PM
Feb-01-22 01:38PM
08:00AM
Jan-24-22 06:15PM
01:53PM
Jan-12-22 12:09PM
Jan-09-22 06:26AM
Jan-06-22 08:17AM
Jan-05-22 06:59AM
Jan-04-22 10:00AM
09:40AM
Dec-22-21 04:37PM
12:36PM
10:41AM
09:07AM
Dec-21-21 07:15PM
Dec-20-21 08:32AM
Dec-08-21 07:38PM
07:38PM
Nov-30-21 07:00AM
Nov-19-21 10:27AM
08:40AM
Nov-08-21 04:05PM
Oct-25-21 08:00AM
Oct-24-21 03:35PM
Sep-30-21 11:12AM
08:39AM
Sep-29-21 08:47AM
Aug-09-21 04:01PM
Jul-29-21 05:31PM
Jul-21-21 06:44AM
Jul-13-21 01:32AM
Jun-07-21 08:00AM
06:12AM
May-24-21 07:00AM
May-21-21 08:57AM
08:08AM
May-10-21 04:01PM
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.